ERK1/2 is highly phosphorylated in melanoma metastases and protects melanoma cells from cisplatin-mediated apoptosis

Journal of Investigative Dermatology

Volumn 127, Issue 9, 2007, Pages 2207-2215

  Mirmohammadsadegh, Alireza ^a   Mota, Rodrigo ^a   Gustrau, Annett ^a   Hassan, Mohammed ^a   Nambiar, Sandeep ^a   Marini, Alessandra ^a   Bojar, Hans ^a   Tannapfel, Andrea ^b   Hengge, Ulrich R ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; CASPASE 3; CISPLATIN; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; RIBOSOMAL S6 KINASE 1; S6 KINASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROTECTION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; MELANOMA CELL; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; PHOSPHORYLATION; SKIN NEOPLASMS;

EID: 34547875411     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/sj.jid.5700870     Document Type: Article

References (33)

1. Arany I, Megyesi JK, Kaneto H, Price PM, Safirstein RL (2004) Cisplatin-induced cell death is EGFR/src/ERK signaling dependent in mouse proximal tubule cells. Am J Physiol Renal Physiol 287:F543-9
2. Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME (1999) Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 286:1358-62
3. Buck M, Poli V, Hunter T, Chojkier M (2001) C/EBPβ phosphorylation by RSK creates a functional XEXD caspase inhibitory box critical for cell survival. Mol Cell 8:807-16
4. Chen RH, Abate C, Blenis J (1993) Phosphorylation of the c-Fos transrepression domain by mitogen-activated protein kinase and 90-kDa ribosomal S6 kinase. Proc Natl Acad Sci USA 90:10952-6
5. Choi BK, Choi CH, Oh HL, Kim YK (2004) Role of ERK activation in cisplatin-induced apoptosis in A172 human glioma cells. Neurotoxicology 25:915-24
6. Cowley S, Paterson H, Kemp P, Marshall CJ (1994) Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 77:841-52
7. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-54
8. Eisenmann KM, VanBrocklin MW, Staffend NA, Kitchen SM, Koo HM (2003) Mitogen-activated protein kinase pathway-dependent tumor-specific survival signaling in melanoma cells through inactivation of the proapoptotic protein bad. Cancer Res 63:8330-7
9. Fisher TL, Blenis J (1996) Evidence for two catalytically active kinase domains in pp90rsk. Mol Cell Biol 16:1212-9
10. Grahn JC, Isseroff RR (2004) Human melanocytes do not express EGF receptors. J Invest Dermatol 123:244-6
11. He H, Wang X, Gorospe M, Holbrook NJ, Trush MA (1999) Phorbol ester-induced mononuclear cell differentiation is blocked by the mitogenactivated protein kinase kinase (MEK) inhibitor PD98059. Cell Growth Differ 10:307-15
12. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O et al. (1999) Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18:813-22
13. Johnson GL, Vaillancourt RR (1994) Sequential protein kinase reactions controlling cell growth and differentiation. Curr Opin Cell Biol 6:230-8
14. Jorgensen K, Holm R, Maelandsmo GM, Florenes VA (2003) Expression of activated extracellular signal-regulated kinases 1/2 in malignant melanomas: relationship with clinical outcome. Clin Cancer Res 9:5325-31
15. Lenormand P, Sardet C, Pages G, L'Allemain G, Brunet A, Pouyssegur J (1993) Growth factors induce nuclear translocation of MAP kinases (p42mapk and p44mapk) but not of their activator MAP kinase kinase (p45mapkk) in fibroblasts. J Cell Biol 122:1079-88
16. Losa JH, Parada Cobo C, Viniegra JG, Sanchez-Arevalo Lobo VJ, Ramon y Cajal S, Sanchez-Prieto R (2003) Role of the p38 MAPK pathway in cisplatin-based therapy. Oncogene 22:3998-4006
17. Mirmohammadsadegh A, Hassan M, Bardenheuer W, Marini A, Gustrau A, Nambiar S et al. (2006) STAT5 phosphorylation in malignant melanoma is mediated through SRC and JAK1 kinases and exerts anti-apoptotic effects. J Invest Dermatol 126:2272-80
18. Mirmohammadsadegh A, Hassan M, Gustrau A, Doroudi R, Schmittner N, Nambiar S et al. (2005) Constitutive expression of EGF receptors on normal human melanocytes. J Invest Dermatol 125:392-4
19. Persons DL, Yazlovitskaya EM, Cui W, Pelling JC (1999) Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin Cancer Res 5:1007-14
20. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM et al. (2003) High frequency of BRAF mutations in nevi. Nat Genet 33:19-20
21. Robinson MJ, Cobb MH (1997) Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 9:180-6
22. Roux PP, Richards SA, Blenis J (2003) Phosphorylation of p90 ribosomal S6 kinase (RSK) regulates extracellular signal-regulated kinase docking and RSK activity. Mol Cell Biol 23:4796-804
23. Sassone-Corsi P, Mizzen CA, Cheung P, Crosio C, Monaco L, Jacquot S et al. (1999) Requirement of Rsk-2 for epidermal growth factor-activated phosphorylation of histone H3. Science 285:886-91
24. Schouten GJ, Vertegaal AC, Whiteside ST, Israel A, Toebes M, Dorsman JC et al. (1997) IkappaB alpha is a target for the mitogen-activated 90 kDa ribosomal S6 kinase. EMBO J 16:3133-44
25. Shahbazi M, Pravica V, Nasreen N, Fakhoury H, Fryer AA, Strange RC et al. (2002) Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 359:397-401
26. Shimamura A, Ballif BA, Richards SA, Blenis J (2000) Rsk1 mediates a MEKMAP kinase cell survival signal. Curr Biol 10:127-35
27. Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22:7265-7
28. Stove C, Stove V, Derycke L, Van Marck V, Mareel M, Bracke M (2003) The heregulin/human epidermal growth factor receptor as a new growth factor system in melanoma with multiple ways of deregulation. J Invest Dermatol 121:802-12
29. Wang X, Martindale JL, Holbrook NJ (2000) Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem 275: 39435-39443
30. Wei SQ, Sui LH, Zheng JH, Zhang GM, Kao YL (2004) Role of ERK1/2 kinase in cisplatin-induced apoptosis in human ovarian carcinoma cells. Chin Med Sci J 19:125-9
31. Woessmann W, Chen X, Borkhardt A (2002) Ras-mediated activation of ERK by cisplatin induces cell death independently of p53 in osteosarcoma and neuroblastoma cell lines. Cancer Chenother Pharmacol 50:97-404
32. Wu YJ, Muldoon LL, Neuwelt EA (2005) The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway. J Pharmacol Exp Ther 312:424-31
33. Xing J, Ginty DD, Greenberg ME (1996) Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase. Science 273:959-63